Skip to main content
Log in

Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The alkylating agent Hepsulfam (Sulfamic acid 1,7-heptanediyl ester, NSC 329680) was developed as a more hydrophilic analog of busulfan. The objective of this study was to determine partitioning of hepsulfam between blood, plasma, and cerebrospinal fluid (CSF) in two female baboons following intravenous administration. Hepsulfam was administered at 11 mg/kg, and blood and CSF levels were determined by gas chromatography with electron capture detection. Blood levels were fairly constant btween animals (17–25 and 20–23 μg/ml) for six hours after administration, following peak levels of 43 and 33 μg/ml, respectively, for the two animals. Peak plasma levels of 35 and 36 μg/ml were achieved, and initial plasma half-lives in babbons were similar to those seen in other species, with at1/2 α of 1 h. The plasma terminal half life of 0.2 h, estimated from limited sampling times, was shorter in baboons than in mice, dogs, or humans. Baboon CSF levels decreased from 1.7 to 0.3 μg/ml during 6h post infusion, and peak concentrations in CSF lagged behind plasma levels. CSF/plasma ratios ranged from 0.33 to 0.62 in one animal, whereas ratios of 0.2–0.25 were maintained in the other animal during the same period. Results from this study indicate hepsulfam will enter the CSF following intravenous administration, and the CSF/plasma ratios are lower than those obtained following oral busulfan administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Brodfuehrer JI, Powis G: Gas chromatographic assay for the new antitumor agent sulfamic acid diester (NSC329680) and its stability in buffer, blood, and plasma. J Chromatogr 427:247–255, 1988

    Article  PubMed  CAS  Google Scholar 

  2. Bisschop JB, Wassom JS: Toxicological review of busulfan (Myleran), Mutat Res 168:15–45, 1986

    Google Scholar 

  3. Santos GW, Tutshka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellits D, Sensenbrenner LL, Stuart PK, Yeager AM: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 309:1347–1353, 1983

    Article  PubMed  CAS  Google Scholar 

  4. Vodopick H, Hamilton HE, Jackson HL, Peng CT, Sheets RF: Metabolic fate of tritiated busulfan in man. J Lab and Clin Med 73:266–276, 1969

    CAS  Google Scholar 

  5. Hassan M, Öberg G, Ehrsson H, Ehrnebo M, Smedmyr B, Tötterman T, Eksborg S, Simonson B: Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur J Clin Pharmacol 26:525–530, 1989

    Article  Google Scholar 

  6. Vassal G, Re M, Gouyette A: Gas chromatographic-mass spectrometry assay for busulfan in biological fluids using a deuterated internal standard. J Chromatrogr Biomed Appl 428:357–361, 1988

    Article  CAS  Google Scholar 

  7. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugières L, Kalifam G, Gouyette A, Lemerle J: Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study. Cancer Res 50:6203–6207, 1990.

    PubMed  CAS  Google Scholar 

  8. Vassal G, Gouyette A, Hartmann A, Pico JL, Lemerle J: Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 24:386–390, 1989

    Article  PubMed  CAS  Google Scholar 

  9. Hassan M, Ehrsson H, Smedmyr B, Tötterman T, Wallin I, Öberg G, Simonsson B: Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplantation 4:113–114, 1989

    PubMed  CAS  Google Scholar 

  10. Brodfuehrer JI, Wilke TJ, Powis G: Pharmacokinetics and metabolism of the antitumor agent sulfamic acid 1,7-heptanediyl ester (sulfamic acid diester) in the mouse and beagle dog. Cancer Chemother Pharmacol 22:120–125, 1988

    Article  PubMed  CAS  Google Scholar 

  11. Ravdin PM, Havlin KA, Marshall MV, Brown TD, Koeller JM, Kuhn JG, Rodriguez G, Von Hoff DD: A phase I clinical and pharmacokinetic trial of hepsulfam. Cancer Res. 51:6268–6272, 1991

    PubMed  CAS  Google Scholar 

  12. Hendricks CB, Grochow LB, Rowinsky EK, Forastiere AA, McGuire WP, Ettinger DS, Sartorius S, Lubejko B, Donehower R: Phase I clinical and pharmacokinetic trials of hepsulfam (NSC 329680). Cancer Res. 51:5781–5785, 1991

    PubMed  CAS  Google Scholar 

  13. Pacheco DY, Stratton NK, Gibson NW: Comparison of the mechanism of action of busulfan with hepsulfam, a new antileukemic agent, in the L1210 cell line. Cancer Res 49:5108–5110, 1989

    PubMed  CAS  Google Scholar 

  14. Marshall MV, Marshall MH, Degen DR, Roodman GD, Kuhn JG, Ross ME, Von Hoff DD:In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units. Stem Cells 11:62–69, 1993

    Article  PubMed  CAS  Google Scholar 

  15. Waud WR, Plowman J, Paull KD, Narayanan VL, Bailey DM, Harrison SD, Dykes DJ, Laster WR, Griswold DP: Preclinical antitumor activity of hepsulfam (NSC-329680). Proc. Am Assn Cancer Res 29:1323, 1988

    Google Scholar 

  16. Berger DP, Winterhalter BR, Dengler WA, Fiebig H-H: Preclinical activity of hepsulfam and busulfan insolid human tumor xenografts and human bone marrow. Anti-Cancer Drugs 3:531–539, 1992

    Article  PubMed  CAS  Google Scholar 

  17. Du D-L, Volpe DA, Grieshaber CK, Murphy Jr MJ: Comparative toxicity of fostreicin, hepsulfam and pyrazine diazohydroxide to human hematopoietic progenitor cellsin vitro. Invest New Drugs 9:149–157, 1991

    Article  PubMed  CAS  Google Scholar 

  18. Pacheco DY, Cook C, Hinks JR, Gibson NW: Mechanisms of toxicity of hepsulfam in human tumor cell lines. Cancer Res 50:7555–7558, 1990

    PubMed  CAS  Google Scholar 

  19. Hinks JR, Adlakha A, Cook CA, Johnson CS, Furmanski P, Gibson NW:In vitro studies on the mechanism of action of hepsulfam in chronic myelogenous leukemia patients. Cancer Res 50:7559–7563, 1990

    Google Scholar 

  20. Geller RB, Janisch L, Kampmeier P, Ratain MJ: Phase I trial of hepsulfam in patients (pts) with refractory leukemia. Proc Soc Am Assn Cancer Res 11:264, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marshall, M.V., Carey, K.D., Von Hoff, D.D. et al. Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons. Invest New Drugs 13, 33–36 (1995). https://doi.org/10.1007/BF02614217

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02614217

Key words

Navigation